The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers

Andrew P. McCarthy, Kjell A. Svensson, Elaine Shanks, Claire Brittain, Brian J. Eastwood, William Kielbasa, Kevin M. Biglan, and Keith A. Wafford

Eli Lilly and Company, Indianapolis, Indiana (K.A.S., W.K., K.M.B.) and Eli Lilly and Company, Surrey, United Kingdom (A.P.M., E.S., C.B., B.J.E., K.A.W.)

Received May 5, 2021; accepted December 3, 2021

ABSTRACT

Dopamine (DA) plays a key role in several central functions including cognition, motor activity, and wakefulness. Although efforts to develop dopamine receptor 1 (D1) agonists have been challenging, a positive allosteric modulator represents an attractive approach with potential better drug-like properties. Our previous study demonstrated an acceptable safety and tolerability profile of the dopamine receptor 1 positive allosteric modulator (D1PAM) mevidalen (LY3154207) in single and multiple ascending dose studies in healthy volunteers (Wilbraham et al., 2021). Herein, we describe the effects of mevidalen on sleep and wakefulness in humanized dopamine receptor 1 (hD1) mice and in sleep-deprived healthy male volunteers. Mevidalen enhanced wakefulness (latency to fall asleep) in the hD1 mouse in a dose-dependent [3–100 mg/kg, orally (PO)] fashion when measured during the light (zeitgeber time 5) and predominantly inactive phase. Mevidalen promoted wakefulness in mice after prior sleep deprivation and delayed sleep onset by 5.5- and 15.2-fold compared with vehicle-treated animals, after the 20 and 60 mg/kg PO doses, respectively, when compared with vehicle-treated animals. In humans, mevidalen demonstrated a dose-dependent increase in latency to sleep onset as measured by the multiple sleep latency test and all doses (15, 30, and 75 mg) separated from placebo at the first 2-hour postdose time point with a circadian effect at the 6-hour postdose time point. Sleep wakefulness should be considered a translational biomarker for the dopamine receptor 1 positive allosteric modulator mechanism.

SIGNIFICANCE STATEMENT

This is the first translational study describing the effects of a selective dopamine receptor 1 positive allosteric modulator (D1PAM) on sleep and wakefulness in the human dopamine receptor 1 mouse and in sleep-deprived healthy male volunteers. In both species, drug exposure correlated with sleep latency, supporting the use of sleep-wake activity as a translational central biomarker for D1PAM. Wake-promoting effects of D1PAMs may offer therapeutic opportunities in several conditions, including sleep disorders and excessive daytime sleepiness related to neurodegenerative disorders.

Introduction

Dopamine (DA) plays a key role in several central functions, including cognition, motor activity, wakefulness, mood, and reward. Several central nervous system (CNS) therapeutics work through the dopaminergic system, for example, DA agonists for Parkinson’s disease and DA releasers (amphetamine-like compounds) for attention-deficit hyperactivity disorders, narcolepsy, and excessive daytime sleepiness (Banerjee et al., 2004). The importance of the dopamine receptor 1 (D1) subtype for higher cognitive functions, such as working memory, attention, and executive function, has triggered interest in developing novel therapeutics, including D1 receptor agonists (Gao et al., 2003; Arnsten et al., 2017; Hall et al., 2019).

Development of novel D1 receptor agonists has been challenging due to poor drug-like properties, including inverted U-shaped dose-response, tachyphylaxis, poor metabolic stability, and tolerability issues. As an alternative to the D1 receptor agonist approach, we recently discovered a series of dopamine...
receptor 1 positive allosteric modulators (D1PAMs) that could address some of the issues associated with D1 receptor agonists and offer a more physiologic approach to activation of D1 receptors with temporal and spatial resolution related to endogenous DA release (Svensson et al., 2017; Bruns et al., 2018; Hall et al., 2019; Svensson et al., 2019). Preclinical studies in transgenic mice expressing the human dopamine receptor 1 (hD1) suggest that selective D1PAMs, while sharing many pharmacological properties with D1 receptor agonists, do not induce inverted U-shaped dose responses or rapid tolerance on various behavioral endpoints (Svensson et al., 2017; Hao et al., 2019; Meltzer et al., 2019). Recently discovered D1PAMs are represented by the close structural analogs DETQ and DPTQ, as well as LY3154207, which also goes under the generic name mevidalen (Hao et al., 2019; Svensson et al., 2019). When dosed in hD1 mice, D1PAMs produce a dose-related increase in forward locomotion and rearing behavior over a wide dose range without induction of stereotyped behaviors that impair locomotion and other functions (Svensson et al., 2017; Hao, et al., 2019). A sleep electroencephalogram (EEG) study in the hD1 mouse with DETQ showed dose-related increases in wakefulness and latency to fall asleep (Brun et al., 2018). In another study, the D1 receptor agonist SKF82958 was also wake-promoting, in agreement with preclinical literature (Isaac and Berridge, 2003). The D1 antagonist SCH39166 was found to be sleep promoting in the hD1 mouse, which is in line with sleep-inducing effects of D1 antagonism in humans (Eder et al., 2003). The wake-promoting effects of D1 receptor activation is likely linked to central arousal effects, including enhanced locomotion and general cortical activation through enhanced release of both acetylcholine and histamine (Brun et al., 2018).

Single and multiple ascending dose studies in healthy male volunteers with mevidalen were recently reported (Wilbraham et al., 2021) where it demonstrated an acceptable safety and tolerability profile with dose-dependent increase in activating adverse events (AEs), e.g., insomnia.

Herein, we present data for mevidalen on sleep-wake activity in the hD1 mouse and in sleep-deprived healthy male volunteers. The preclinical studies with DETQ demonstrated an hD1-mediated wake-promoting effect that could serve as a translatable biomarker to demonstrate central penetration and confirm target engagement in humans. Wake-promoting effects of d-amphetamine, modafinil, and the histamine 3 receptor antagonist MK-0249 have been demonstrated in single-dose administration studies with sleep deprivation used to induce increased sleep pressure (Chapotot et al., 2003; James et al., 2011), and these compounds have also been shown to have wake-promoting effects in rodent studies (Stocking and Letavic, 2008). In further support of the translatability of sleep signals, basic phenomenological aspects of rodent and human sleep, such as rapid eye movement (REM) versus nonrapid eye movement (NREM) states and homeostatic versus circadian influences, have similar underlying physiologic mechanisms, often with a homologous chemo-neuroanatomy (Leiser et al., 2011; Brown et al., 2012). However, there are important differences between rodent and human sleep. First, rodents are night active (nocturnal) and they are awake during about two-thirds of the dark period and one-third of the light period, whereas humans in general are day active. Also, rodents sleep in short naps throughout the circadian cycle, whereas humans generally consolidate their sleep into one or two periods per day. Thus, although the underlying sleep physiology may be similar, these timing differences require care in selecting the timing of drug administration and the background sleep pressure when comparing rats and mice with humans. In this work, we present the preclinical work to demonstrate mevidalen’s wake-promoting properties in rodents and a clinical trial in healthy male volunteers that demonstrates for this mechanism that this biomarker translates to humans and thereby confirms central target engagement at tolerable doses.

Materials and Methods

Nonclinical

All experimental procedures were preapproved by the local animal care and use ethical committee, according to National Institutes of Health guidelines and the Declaration of Helsinki. In the United Kingdom, all procedures were carried out in accordance with the UK Animals Scientific Procedures Act (1986) and associated guidelines, as well as the European Communities Council Directive of November 24, 1986 (86/609/EEC). All procedures passed the Lilly UK ethical review. The Eli Lilly and Company animal care and use program is fully accredited by the Association for Accreditation of Laboratory Animal Care.

Animals, Housing, and Care. Transgenic male mice in which the mouse D1 receptor was replaced with the human D1 were derived as previously described (Svensson et al., 2017). The strain was maintained in the homozygous state. The hD1 mice were bred at Charles River (Margate, UK) and animals were 27–52 weeks of age. Age matched male wild-type C57Bl/6 Ntac mice were also purchased from Charles River (Margate, UK) for preliminary pilot studies. Genotyping was routinely performed by the breeder.

Surgery. EEG recordings were made using tethered mice. Surgery was performed by in-house surgeons. Subjects were anesthetized and sedated (2% isoflurane in 100% oxygen, 0.1 mg/kg medetomidine hydrochloride subcutaneous injection) and fitted with a cranial implant affixed to the skull by dental acrylic and cyanoacrylate. The cranial implant consisted of bilateral stainless-steel screws (two frontal (+2mm AP from bregma, ±2mm ML) and two occipital (−3mm AP, ±2mm ML) for EEG recordings. For Electromyography (EMG) recordings, two Teflon-coated stainless-steel wires were positioned under the nuchal trapezius muscles. Atipamezole (0.5 mg/kg, s.c.) was administered to reverse the medetomidine. Carprofen (5 mg/kg, s.c.) was administered preoperatively, postsurgery, and on the morning of the first postoperative day. Cefovecin (8 mg/kg, s.c.) was administered postsurgery. Body temperature and locomotor activity were monitored via a miniature transmitter (Minimitter G2Emitter, Philips Respiricomics, Bend, OR) placed in the abdomen during the same surgical procedure. In addition, a nonsteroidal anti-inflammatory drug (meloxicam 0.15 mg/kg) was administered orally twice daily for 6 days postsurgery. Prophylactic antibiotic treatment (cefalexin 20 mg/kg) consisted of an oral dose 24 hours prior to and immediately before surgery and twice daily for 7 days after surgery (Looms et al., 2015). At least 2 weeks were allowed for recovery from surgery.

In the first sleep study, the home cage is the recording cage (Hanley et al., 2019). Each animal was housed individually within a specially modified Ancare microisolator cage having a custom polycarbonate filter-top riser and a custom ultra-low-torque slip-ring commutator (Hypermion, Inc.) on a 12-hour light/dark cycle with free access to standard animal laboratory food and water. Each cage was located within separate, ventilated compartments of stainless-steel sleep-wake recording chamber and had an infrared light source and digital video cameras to allow a minimum of twice-daily remote visual monitoring. Animals were undisturbed for 48 hours before and after each treatment. All treatments were administered at zeitgeber time (ZT)-5, 5 hours after the start of the light cycle). This dosing time resulted from an empirically optimized assessment of the evaluation of wake-
promoting compounds (Edgar and Seidel, 1997; Olive et al., 1998). A general outline of the preclinical testing scheme is shown in Fig. 1A.

Sleep Restriction. To examine the effect of mevidalen preclinically in a paradigm more closely resembling a healthy volunteer human pharmacology study, in a second study we increased sleep pressure over the first protocol by employing sleep deprivation prior to the dosing of compound. To employ sleep restriction (SR), mice were housed in individually custom-designed SR chambers during the course of the sleep study. Each chamber consisted of a cylinder constructed of plexiglass rods positioned horizontally inside a plexiglass frame. During periods of SR, after the real-time detection of a NREM sleep epoch, a motor rotated the cylindrical SR chamber around its axis in a pseudo-random direction for 10 seconds. This movement caused a mild vestibular stimulus sufficient to initiate immediate awakening. Our method of inducing physiologic SR did not reduce time asleep to zero, rather the amount of functionally effective sleep was zero since no sleep bout was longer than 10 seconds; a reliable, reproducible amount of sleep loss was achieved (Hanley et al., 2019). The sleep restriction period, between ZT-0 and ZT-5, is shown in Fig. 1A. Overall, mice undergoing the sleep restriction lost 79.3% of their sleep relative to baseline (7.5 minutes of sleep per hour versus 36.3 minutes per hour during the baseline), and the remaining sleep was limited to periods no longer than 10 seconds of NREM sleep before the activation of the wheel. REM sleep was completely abolished using this protocol. On average, the animals attempted to sleep 45 times per hour, causing activation of the wheel.

Test Compound. Mevidalen (Synonyms: mevidalen, LY3154207 hydroxybenzoate) chemically known as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3,4-dihydro-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-2(1H)-isoquinolinyl]ethanone (Hao et al., 2019) was administered as parent compound or the hydroxybenzoate co-crystal form (as indicated in the result section). For animal studies, drug formulations occurred immediately before each treatment. Test drug was weighed using a Mettler Toledo AB104-S analytical balance (d = 0.1 mg), then mixed with vehicle (20% hydroxypropyl betacyclodextrin) using a sterile ground glass mortar and closely fitting pestle (i.e., tissue homogenizer) of appropriate volume until finely suspended, and transferred using multiple washes to a clean screw-top glass vial. Suspensions were agitated immediately before being drawn into a syringe for oral administration by gavage. Mice were dosed orally (PO) by gavage using a dose volume of 10 mL/kg. To administer the treatment, each mouse was removed from its cage for about 60 to 90 seconds to be weighed and treated.

Measurement of Sleep and Wakefulness in hD1 Mice. Sleep and wakefulness were determined using SCORE-2000, a microcomputer-based sleep-wake and physiologic monitoring system (Van Gelder et al., 1991). In the present study, the system monitored amplified EEG [X10,000, bandpass 0.1-30 Hz (Grass Corp., Quincy, MA); initial digitization rate 400 Hz], integrated EMG (bandpass 10–100 Hz, RMS integration), and telemetered body temperature and nonspecific locomotor activity (LMA) from all mice simultaneously in each experiment. Vigilance states were classified online as NREM sleep, REM sleep, wake, or theta-dominated wake every 10 seconds using EEG period and amplitude feature extraction and ranked membership algorithms. Individually taught EEG-arousal-state templates and EMG criteria differentiated states of arousal. Spectral frequency bands were delta (0.5 to 4 Hz), theta (5.1 to 9 Hz), alpha (9.1 to 12 Hz), and beta (12 to 20 Hz),

---

**Fig. 1.** Experimental designs for sleep EEG studies in the mouse (A) and humans (B). CRU = clinical research unit.
based on internal and external data (Holton et al., 2020). Total power was selected as 0.1 to 30 Hz.

Pharmacokinetics. Mevidalen was given to a satellite group of fed male CD-1 mice (N = 6 per dose group with 3/timepoint) as a single oral dose of 3, 10, 30, 60, and 100 mg/kg. The dosing formulation used mevidalen mixed with vehicle (20% hydroxypropyl betacyclodextrin). Blood samples were collected at 0.25, 0.5, 1, 2, 4, 7, 12, and 24 hours postdose from orbital sinus bleeding and a terminal cardiac puncture. The plasma samples were analyzed for mevidalen using a non-GLP liquid chromatography with tandem mass spectrometry bio-analytical method (Hao et al., 2019).

Statistical Analysis. All statistical analyses were performed using version 9.4 of the SAS System for Windows (Cary, NC) and plots created using GraphPad Prism version 9.0.0 for Windows (GraphPad Software, San Diego, CA, www.graphpad.com). Sleep was evaluated over the 60-hour recording period shown in Fig. 1A. To quantify the compound effects on sleep/wake parameters, the 12-hour light (0–12 hours) and dark (12–24 hours) periods were used to characterize baseline sleep. On the day of drug administration, the period of 5–12 hours of lights after drug administration was used to estimate sleep latency. Sleep latency was defined as the time to the first minute of continuous sleep after drug administration, whereas REM sleep latency was defined as the duration from the onset of sleep to the first 20 seconds of REM sleep. Other sleep/wake parameters were also evaluated in this period. Finally, the recovery phase was evaluated as two separate light and dark periods 7 to 19 hours and 19 to 31 hours after drug administration. To represent the homeostatic bookkeeper, the accumulated minutes of wakefulness were calculated as the accumulated sum difference to baseline at each hour after the treatment.

All outcomes were analyzed by a mixed-model repeated measures analysis of variance using treatment (drug dose) and treatment date as factors and a compound-symmetry covariance structure to model multiple drug treatments on the same animal. Contrasts were used to test for statistical significance of the change from vehicle for each dose. Sleep latency and other outcomes analyzed on the log scale were back-transformed to report geometric means and mean ratio-to-vehicle results, denoted in the table of results as n-fold differences from vehicle. Post-hoc analyses were performed using Tukey’s honestly significant differences test.

Clinical

Protocols for both the studies were reviewed and approved by the Independent Institutional Review Board before study start. Written informed consent was obtained from all subjects before study participation. Both studies were conducted in accordance with the International Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the International Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.

Subjects. The study enrolled overtly healthy males who are at least 18 years old and who had a body mass index of 18 to 35 kg/m². The original principles embodied by the Declaration of Helsinki. The Conference on Harmonization guideline for Good Clinical Practice and the original principles embodied by the Declaration of Helsinki. The studies are registered at ClinicalTrials.gov as NCT02603861.
levels of sleepiness during the last 5 minutes (Kaida et al., 2006; Miley et al., 2016). The scale ranges from 1 = very alert to 9 = very sleepy, great effort to stay awake or fighting sleep. A score of 7 or more indicates excessive sleepiness. KSS was measured before dosing on day 1 as well as 5 minutes before and after each MSLT assessment performed at the postdose time points of 2, 4, 6, and 8 hours. Baseline was defined as the predose value on day 1. Change from baseline in KSS was calculated and summarized by treatment group and time point.

Pharmacokinetics. At doses of 15 mg, 30 mg, and 75 mg, blood samples were collected at predose and at 1, 3, 5, 7.5, and 9 hours postdose on day 1 and day 14 of the study design to measure plasma concentrations of mevidalen. Plasma concentrations of mevidalen were assayed using a validated liquid chromatography/tandem mass spectrometry method at Covance Laboratories Inc. (Madison, WI). The lower limit of quantification of mevidalen plasma was 0.500 ng/mL, and the upper limit of quantification was 2500 ng/mL (Wilbraham et al., 2021). From the mevidalen plasma concentration-time data, standard noncompartmental methods of analysis were used to calculate the time to maximal concentration (t_{max}), the C_{max}, the area under the plasma concentration-time curve from time 0 to infinity and the area under the concentration versus time curve from 0 to 24 hours.

Exposure-Response Analysis. The objective of the exposure-response (ER) analysis was to assess the relationship between mevidalen plasma concentrations and sleep effects in human and mouse. In human, MSLT evaluations were performed at 2, 4, 6, and 8 hours postdose, and pharmacokinetic (PK) blood samples were collected at 1, 3, 5, and 7.5 hours during the MSLT time frame. To time-match the MSLT observations with mevidalen plasma concentrations for the ER analysis, a population PK model (not reported herein) that provided an adequate fit to the observed mevidalen PK was developed. Subsequently, a model-based PK simulation was conducted to predict the mevidalen plasma concentration for each individual at each MSLT time point based on their PK model parameter estimates. In the mice, individual PK parameter estimates were not possible due to the nature of the study, and therefore only treatment group PK levels were estimated from the average latency to sleep. A log-linear fit to the data were performed using GraphPad Prism version 9.0.0 for Windows.

Safety Assessments and Analyses. Safety data included documentation of AEs, safety laboratory parameters, ECG parameters, and vital signs. Suspected unexpected serious adverse reactions were defined as serious events that were not listed in the Investigator’s Brochure and that investigator identified as related to investigational product or procedure. Clinical and laboratory AEs were coded according to the Medical Dictionary for Regulatory Activities (version 18.0).

Results

Nonclinical

Effect of Mevidalen on Sleep and Wakefulness in Human D1 Knock-In Mice. Preliminary studies of mevidalen in hD1 and wild-type mice confirmed on-target hypothesis of mevidalen’s wake-promoting properties (not shown). In the dose-response study in the hD1 mouse with mevidalen dosed at ZT-5, mevidalen showed a rapid onset of the wake-promoting effects in a dose-dependent fashion with a delay to the onset to sleep (Fig. 2, A–C and Fig. 3A). Relative to the vehicle-control animals, which required on average 34 ±3 minutes to fall asleep, the dose-related increase in sleep latency ranged from 1.4-fold to 9.7-fold longer (Fig. 3A), a statistically significant result at all doses (3–100 mg/kg, PO). NREM sleep

![Pharmacodynamic effects of mevidalen on wakefulness in hD1 mice for the placebo (n = 21), 10 mg/kg (n = 10), 30 mg/kg (n = 11), and 60 mg/kg (n = 12) groups: (A) hourly plot showing baseline, treatment, and recovery periods after drug administration at ZDCT-5 (5 hours after lights on), (B) the first 5 hours after treatment in 5-minute bins, and (C) accumulated minutes of wakefulness over 29 hours post-treatment. Dark phases are represented by gray shaded regions, and dosing at ZT-5 by a black vertical line.](image-url)
reductions during the first 7 hours post-treatment was also dose-related and statistically significant starting at 20 mg/kg (Supplemental Table 3). In all treatment groups, wake-promoting efficacy subsided within the first 7 hours with little evidence of a rebound-like increase in sleep. Overall, accumulated wakefulness was lost in small increments of sleep during the subsequent dark period at the 30 and 60 mg/kg doses. (Fig. 2C).

Effects of Mevidalen on Sleep Latency in Sleep-Deprived hD1 Mice. Mevidalen maintained equivalent wake-promoting effects in mice subjected to 5 hours of prior sleep restriction using the custom-designed SR chambers. After 20 mg/kg PO of mevidalen, mice fell asleep on average, in 107 ±7 minutes, or 5.5-fold longer than the vehicle controls, which took on average 19.5 ±2 minutes (P < 0.0001, Fig. 3B), which was not significantly different to the 125 ±9 minutes, 4-fold longer than their vehicle controls (P < 0.0001) seen without prior sleep deprivation. At the 60 mg/kg PO dose level of mevidalen, mice subjected to 5 hours of sleep restriction fell asleep, on average, in 297 ±20 minutes, 15.2-fold longer than their vehicle controls (P < 0.0001, Fig. 3B), which was once again not significantly greater than the 250 ±19 minutes, 8.1-fold longer than their vehicle controls (P < 0.0001, Fig. 3B) seen without prior sleep deprivation.

Pharmacokinetics. The pharmacokinetics of mevidalen at doses of 3–100 mg/kg in the satellite group of mice are presented in Supplemental Fig. 1. Across doses, the mean $t_{\text{max}}$ ranged from 0.25–0.5 hours and the mean half-life ranged from approximately 2–3 hours. Mevidalen demonstrated an approximately dose proportional increase in $C_{\text{max}}$ and area under the concentration versus time curve from 0 to 24 hours (Supplemental Table 1).

Clinical Effects of Mevidalen on Sleep Latency in Sleep-Deprived Healthy Subjects using MSLT. Mevidalen significantly increased sleep latency at all doses in the first sleep latency test (Fig. 4A). However, at later time points, as sleep
pressure continues to build and the quantity of drug reduces, the treatment effect disappears. Consistent with the results from the analysis by time point in the overall MSLT, mevidalen demonstrated dose-dependent increases in sleep latency within the MSLT (Fig. 5). Based on the least squares mean differences compared with placebo (where subjects remained awake for only 40.2 seconds, 95% confidence interval (CI) 10.1, 121.8), the mevidalen 75mg dose group had a 5.2-minute increase compared with placebo (95% CI: 3.31,7.10), and at the 30mg dose had a 3.2-minute difference (95% CI: 1.35, 5.06). On average, mevidalen did not significantly increase sleep latency at the 15 mg dose (estimate = 1.95 minute, 95% CI: 0.40, 3.51), but the time series plots indicate efficacy at the 2-hour post-treatment time point (Fig. 4B).

In a covariate analysis investigating the effects of machine and technician used for the MSLT, no notable differences were seen for either of these factors. In addition, no significant period effect was observed, although it appears that subjects, on average, took longer to fall asleep during their first MSLT assessment in period 1. However, this was already accounted for by the planned inclusion of period as a fixed effect in the MMRM analysis.

**Effects of Mevidalen on Sleepiness in Sleep-Deprived Healthy Subjects Using KSS.** A line plot of mean KSS scores predose and at each postdose time point (pre- and post-MSLT) is presented by treatment group in Fig. 4B. Mean scores indicated a clear dose response with the mevidalen 75mg dose group having the largest increase in levels of alertness compared with the other mevidalen dose groups and placebo. This is consistent with the same dose response observed for sleep latency from the MSLT. However, the circadian effect observed in the mevidalen 75mg dose group having the largest increases in levels of alertness compared with the other mevidalen dose groups and placebo. This is consistent with the same dose response observed for sleep latency from the MSLT.

**Pharmacokinetics.** The plasma concentration—time profile of mevidalen at doses of 15, 30, and 75 mg—are shown in Supplemental Fig. 2 and the PK parameters are summarized in Supplemental Table 2. Across all dose levels, t\textsubscript{max} was achieved at about 3 hours, and C\textsubscript{max} and area under the concentration versus time curve increased in a dose proportional manner. The PK profile of mevidalen in this study was consistent with what has been reported previously (Wilbraham et al., 2021).

**Exposure-Response Relationship for Human and Mouse.** Fig. 6 illustrates the ER relationship between mevidalen plasma concentrations (log scale) and increase in sleep latency for human and mouse in the nonsleep deprivation experiment. The ER was dose proportional within the ranges tested, and for each species the data were characterized using a linear regression model. The slope and y-intercept was 6.16 and −8.04 for human and 5.92 and −11.1 for mouse, respectively, indicating an increasing wake-promoting ER in both species. The similarity of the slopes suggests similar fold increases in wake promotion for equivalent exposure increases.

**Safety and Tolerability.** No deaths, serious AEs, or discontinuations due to AE occurred. All AEs were mild in severity. A total of 12 treatment-emergent adverse events (TEAEs) were reported by nine subjects, the most common of which was contact dermatitis (four subjects). No other TEAEs occurred in more than one subject. Of the 17 subjects who received one more dose of study treatment, two subjects (11.8%) reported two AEs that were considered related to treatment. One subject experienced mild somnolence after receiving mevidalen 15mg. There were no apparent drug- or dose-related trends in the clinical laboratory data and 12-lead ECG parameters (with the exception of dose-related increases in pulse rate and blood pressure) after doses of mevidalen consistent with previous trials of mevidalen in healthy volunteers (Wilbraham et al., 2021).

**Discussion**

This is the first translational study describing the effects of a selective and brain penetrant D1PAM on sleep wakefulness in the hD1 mouse and in sleep-deprived healthy volunteers. In human and mouse, exposure was correlated to sleep latency, supporting the use of sleep-wake activity as a central biomarker for the D1PAM mechanism. In addition, these
data support several therapeutic opportunities, including excessive daytime sleepiness, narcolepsy, and other disorders related to impaired circadian rhythms.

Dopamine releasers, such as d-amphetamine, are used clinically to increase wakefulness, and D1 receptor agonists have been shown to cause behavioral activation with increased wakefulness and reduced sleep in animals (Isaac and Ber-ridge, 2003). Conversely, D1 receptor antagonists increase slow wave and REM sleep with reduced time spent awake both in animals (Monti et al., 1990) and in humans (Eder et al., 2003). We recently reported that the selective DIPAMs DETQ and mevidalen produce dose-dependent increases in locomotion in hD1 mice, similar to D1 receptor agonists, but importantly without inducing inverted U-shaped dose responses (Svensson et al., 2017; Hao et al., 2019). In addition, DETQ showed dose-related increases in wakefulness and reduced sleep in hD1 mice, and these effects were similar to a D1 receptor agonist but opposite to a D1 antagonist in this model (Bruns et al., 2018). The mechanism by which DIPAMs increase wakefulness is likely via enhanced receptor activation from the naturally present dopamine and subsequently enhanced release of acetylcholine and histamine in cortical and subcortical areas (Bruns et al., 2018; Hao et al., 2019). Both neurotransmitters are well-known to have arousal and wake-promoting effects (Watson et al., 2010).

In this report, we found that mevidalen enhanced wakefulness (latency to fall asleep) in the hD1 mouse in a dose-dependent fashion when measured during the light (ZT-5) and predominantly inactive phase. This is in agreement with previous studies (Svensson et al., 2017; Hao et al., 2019), where increased wakefulness and motor stimulation were observed at doses that produced unbound brain drug levels in the hD1 mouse around the EC50 value in the in vitro hD1 cAMP assay (3 nM). After the wake-promoting effect of mevidalen, there were no significant rebound-like increases in NREM sleep. However, there was some gradual recovery of lost sleep throughout the dark period at the highest doses. The lack of a rebound increase in sleep after extended waking is similar to what is reported for modafinil (Edgar and Seidel, 1997) but different from what is observed with traditional stimulants like d-amphetamine (Hanley et al., 2019). The duration of the wake-promoting effects also paralleled increases in locomotor activity (data not shown).

Treatments for disorders of excessive sleepiness have to remain effective in situations of high sleep pressure. In the current study in hD1 mice, mevidalen or vehicle was administered at ZT-5 either with or without a prior sleep restriction of 5 hours. Mevidalen was clearly still wake-promoting after prior sleep deprivation with 5.5- and 15.2-fold longer times to fall asleep when compared with the vehicle-treated animals after the 20 and 60 mg/kg PO doses, respectively. Wake time was similar to that without sleep restriction, suggesting that the additional sleep pressure did not reduce the efficacy.

In the human study, 24-hour sleep-deprived subjects were dosed and 2 hours later allowed to fall asleep within a 20-minute interval. Subjects were awakened and asked to leave the test room as soon as sleep onset has occurred. In this way, sleep propensity should have minimally affected the repeated testing. The test was repeated every 2 hours throughout the day (Seidel et al., 1984; Mittler et al., 1998).

Consistent with the preclinical findings in hD1 mice, mevidalen demonstrated a dose-dependent increase in SL, and all doses showed significant effects separated from placebo at the first 2-hour postdose time point (Fig. 4A). Based on the least squares mean differences compared with placebo, the 75 mg dose had a 5.2-minute difference compared with placebo. A delay in sleep latency of this magnitude represents a clinically meaningful effect based on available literature for modafinil (Minzenberg and Carter, 2008), which is marketed as a wakefulness-promoting agent. For example, a phase 3 study of armodafinil 150 mg versus placebo for jet lag showed a total increase of sleep latency of 6.9 minutes (Rosenberg et al., 2010). However, in the present study, modafinil did not show a statistically significant effect relative to placebo on SL as measured in the MSLT overall or at any time point. Pharmacokinetic analyses of modafinil in plasma samples revealed levels in agreement with published data (Wong et al., 1999; Darwish et al., 2009) for the 200 mg dose of modafinil (data not shown). This contrasts with previous reports that modafinil increases SL in the MWT (Chapotot et al., 2003; Dinges et al., 2006; Iannone et al., 2010; James et al., 2011), and we did not expect the variation in primary endpoints to affect the outcome of modafinil. However, the use of MWT remains the principal difference in methodology between those studies and ours. In the MSLT, the subject is told to try to sleep, whereas in the MWT they are told to remain awake. These findings suggest that the motivational instruction given to the subject affects modafinil performance, but this hypothesis would have to be confirmed in future studies.

Further support of the clinical meaningfulness of the changes in MSLT with mevidalen, a dose-dependent decrease in subjective sleepiness as measured by the KSS was seen, with the greatest increases in alertness occurring at the 75 mg dose. The wake-promoting effects of mevidalen observed in this study are also consistent with previous phase 1 safety studies where higher doses of mevidalen resulted in CNS-activating adverse events, including insomnia (Wilbraham et al., 2021). Safety and tolerability were overall consistent with our previous studies (Wilbraham et al., 2021). Only a very small number of treatment emergent adverse events (TEAEs) were reported, regardless of causality (data not shown). The most common TEAE was contact dermatitis. No other TEAE occurred in more than one subject. As a result, we believe mevidalen to be safe for further evaluation in an efficacy study in disorders of excessive sleepiness.

Analyses were conducted to assess the relationship between mevidalen plasma concentrations and sleep latency in humans and mice. Our findings show a parallel relationship between species (similar slope) across the concentration range examined, but sleep effects in human can be achieved at lower mevidalen plasma concentrations than mouse (Fig. 6). Based on the linear regression analysis results, a 5-fold increase in sleep latency compared with vehicle/placebo would require a mevidalen plasma concentration of about 524 ng/mL in mouse and 130 ng/mL in human with a potency ratio (human/mouse) to be about 4.

Possible explanations may be that the design and methods of the studies in mice and humans necessarily have differences, and there may be biologic differences between species, resulting in different sleep patterns across species. SL in rodents is measured immediately after dosing versus 2 hours postdose in humans. No instructions can be given to rodents. Pharmacologically mevidalen shows about 30-fold higher potency for the human versus the mouse D1 receptor (Hao
et al., 2019). Although we used the fully humanized D1 mouse for current studies, these animals show about 50% lower D1 receptor expression in the brain as compared to their corresponding wild types (Svensson et al., 2017). This, together with potential differences in signal transduction mechanisms such as G-protein receptor coupling, could possibly contribute to the human/mouse potency ratio described above. We have estimated previously that the human Kpu,u (CSF concentration/unbound plasma ratio) is about 0.3 (Wilbraham et al., 2021) and similar to that of mouse (Hao et al., 2019), so it does not appear that the more potent sleep effects in human are driven by enhanced mevidalen penetration into the CNS. These data are important in understanding the translatability of mevidalen dose (slightly longer sleep latency from the 75mg dose (slightly longer sleep latency onset state), but, importantly, the sleep architecture was not disrupted. This is important information for a future chronic dosing study. Regular sleep is a tractable central biomarker for the D1PAM molecule with wake-promoting activity that is not being developed for that indication. 

In conclusion, these results suggest that increased wakefulness is a translatable central biomarker for the D1PAM molecule with wake-promoting activity that is not being developed for that indication. 

Acknowledgments

The authors wish to acknowledge the subjects, investigators, and clinical staff involved in the study as well as Sumit Arora for providing medical writing services on behalf of Covance, Inc.

Authorship Contributions

Participated in research design: Svensson, Kielbasa, Biglan, Wafford. Conducted experiments: Shanks.

Performed data analysis: Svensson, Kielbasa, Biglan, Wafford.

Wrote or contributed to the writing of the manuscript: McCarthy, Svensson, Shanks, Brittman, Eastwood, Kielbasa, Biglan, Wafford.

References

Arnsten AF, Girgis RR, Gray DL, and Mailman RB (2017) Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry 81:67–71.

Buneneke D, Vitello MV, and Grunstein RR (2004) Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 8:339–354.

Biglan K, Munisie L, Svensson KA, Ardayfo P, Pugh M, Sims J, and Brys M (2021) Efficacy and safety of mevidalen, a D1 receptor positive allosteric modulator: a phase 2 randomized placebo-controlled trial for the treatment of cognition in patients with Lewy Body Dementia. Mov Disord [published ahead of print].

Brown RE, Basheer R, McKenna JT, Strecker RE, and McCarley RW (2012) Control of sleep and wakefulness. A review. Sleep Med Rev 16:345–387.

Bruns RF, Mitchell SN, Wafford KA, Harper AJ, Shanks EA, Carter G, O’Neil MJ, Murray TK, Eastwood BJ, Schaum JM, et al. (2018) Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders. Neuropharmacology 129:351–365.

Chapotot F, Pigeau R, Canini F, Bourdon L, and Buguet A (2003) Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. J Neurochem 84:127–138.

Darwish M, Kirby M, Hellriegel ET, and Robertson JR (2019) Armofadinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, phamacokinetic studies. Clin Drug Invest 39:613–623.

Dinges DF, Arora S, Darwish M, and Niemeyer GE (2006) Pharmacodynamic effects on alertness of single doses of armofadinil in healthy subjects during a nocturnal period of acute sleep loss. J Pharmacol Exp Ther 317:155–163.

Eder DN, Zdravkovic M, and Wildschütt G (2003) Selective alterations of the first NREM sleep cycle in humans by a dopamine D1 receptor antagonist (NNC-687). J Psychopharmacol 17:305–312.

Edgar DM and Seidel WF (1997) Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 283:275–279.

Gao WJ, Wang Y, and Goldman-Rakic PS (2003) Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J Neurosci 23:1622–1630.

Hall A, Provins L, and Valade A (2019) Novel strategies to activate the dopamine D1 receptor: recent advances in orthosteric agonism and positive allosteric modulation. J Med Chem 62:128–140.

Hanley N, Paulissen J, Eastwood BJ, Gilmore G, Loomis S, Wafford KA, and McCarthy A (2019) Pharmacological modulation of sleep homeostasis in rat: novel effects of an mGluR5 antagonist. Sleep (Basel) 42:xxx123.

Hao J, Beck JP, Schaus JM, Krushinski JH, Chen Q, Beadle CD, Vidal P, Reinhard MH, Dressman BA, Massey SM, et al. (2019) Synthesis and pharmacological characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R,5S)-5-hydroxy-3-methylbutyl)-3-hydroxy-methyl-1-methyl-3,4-dihydroisoquinolin-2(1H)-ylenethione (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human dopamine D1 receptor. J Med Chem 62:871–872.

Holtz CM, Hanley N, Shanks E, Oxley P, McCarthy A, Eastwood BJ, Murray TK, Nickerson A, and Wafford KA (2020) Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration. Alzheimers Res Ther 12:84.

Iannone R, Palca J, Renger JJ, Calder N, Cerchio K, Gottesdiener K, Hargreaves R, Dijk DJ, Boyle J, and Murphy MG (2010) Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin Pharmacol Ther 88:831–839.

Isaac SO and Berridge CW (2003) Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J Pharmacol Exp Ther 307:386–394.

James LM, Iannone R, Palca J, Renger JJ, Calder N, Cerchio K, Gottesdiener K, Hargreaves R, Murphy MG, Boyle J, et al. (2011) Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) 215:643–653.

Kaida K, Takahashi M, Akerstedt T, Nakata A, Otsuka Y, Haratani T, and Fukasawa H (2015) Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator, DETQ, ameliorates subchronic and excessive daytime sleepiness related to neurodegenerative disorders. Brain 138:1630–1642.

Leiser SC, Dunlop J, Bowley MR, and Devilbiss DM (2011) Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol 84:1408–1423.

Loomis S, McCarthy A, Baeter C, Kellett DO, Edgar DM, Tricklebush M, and Gilmore G (2015) Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814107. Psychopharmacology (Berl) 232:3977–3989.

Meltzer HY, Rajagopal L, Martrone F, Hao J, Svensson KA, and Huang M (2019) The allosteric dopamine D1 receptor potentiator, DETQX, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behav Brain Res 361:139–150.
Miley AA, Kecklund G, and Åkerstedt T (2016) Comparing two versions of the Karolinska Sleepiness Scale (KSS). *Sleep Biol Rhythms* **14:**257–260.

Minzenberg MJ and Carter CS (2008) Modafinil: a review of neurochemical actions and effects on cognition. *Neuropsychopharmacology* **33:**1477–1502.

Mitler MM, Walsleben J, Sangal RB, and Hirshkowitz M (1998) Sleep latency on the maintenance of wakefulness test (MWT) for 830 patients with narcolepsy while free of psychoactive drugs. *Electroencephalogr Clin Neurophysiol* **107:**33–38.

Monti JM, Fernández M, and Jantos H (1990) Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats. *Neuropsychopharmacology* **3:**153–162.

Olive MF, Seidel WF, and Edgar DM (1998) Compensatory sleep responses to wakefulness induced by the dopamine autoreceptor antagonist (+)-DS121. *J Pharmacol Exp Ther* **285:**1073–1083.

Rosenberg RP, Bogan RK, Tiller JM, Yang R, Youakim JM, Earl CQ, and Roth T (2010) A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. *Mayo Clin Proc* **85:**630–638.

Seidel WF, Roth T, Roehrs T, Zorick F, and Dement WC (1984) Treatment of a 12-hour shift of sleep schedule with benzodiazepines. *Science* **224:**1262–1264.

Stocking EM and Letavic MA (2008) Histamine H3 antagonists as wake-promoting and pro-cognitive agents. *Curr Top Med Chem* **8:**988–1002.

Svensson KA, Hao J, and Bruns RF (2019) Positive allosteric modulators of the dopamine D1 receptor: a new mechanism for the treatment of neuropsychiatric disorders. *Adv Pharmacol* **86:**273–305.

Svensson KA, Heinz BA, Schaus JM, Beck JP, Hao J, Krushinski JH, Reinhard MR, Cohen MP, Hellman SL, Getman BG, et al. (2017) An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis. *J Pharmacol Exp Ther* **360:**117–128.

Van Gelder RN, Edgar DM, and Dement WC (1991) Real-time automated sleep scoring: validation of a microcomputer-based system for mice. *Sleep* **14:**48–55.

Watson CJ, Baghdoyan HA, and Lydic R (2010) Neuropharmacology of sleep and wakefulness. *Sleep Med Clin* **5:**513–528.

Wilbraham D, Biglan KM, Svensson KA, Tsai M, and Kielbasa W (2021) Safety, tolerability, and pharmacokinetics of mevidalen (LY3154207), a centrally acting dopamine D1 receptor-positive allosteric modulator (D1PAM), in healthy subjects. *Clin Pharmacol Drug Dev* **10:**392–403.

Wong YN, Simone D, Hartman LN, Laughton WB, King SP, McCormick GC, and Grebow PE (1999) A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. *J Clin Pharmacol* **39:**38–49.

Address correspondence to: Andrew P. McCarthy, Eli Lilly and Company, 450 Kendall Square, Cambridge, MA 02142. E-mail: mccarthy_andrew_peter@lilly.com
The dopamine D1 receptor positive allosteric modulator mevidalen (LY3154207) enhances wakefulness in the humanized D1 mouse and in sleep deprived healthy volunteers

Andrew P McCarthy*, Kjell A Svensson¹a, Elaine Shanks², Claire Brittain²b, Brian J Eastwood², William Kielbasa¹, Kevin M Biglan¹, Keith A. Wafford²c

¹Eli Lilly and Company, Indianapolis, Indiana USA
²Eli Lilly and Company, Erl Wood Manor, Surrey, United Kingdom

The Journal of Pharmacology and Experimental Therapeutics

(http://jpet.aspetjournals.org/content/ifora)
Supplementary Data

**Supplementary Table 1**: Mevidalen Pharmacokinetic Parameters in Mice

| Parameter     | Units            | Dose (mg/kg) |
|---------------|------------------|--------------|
|               |                  | 3 | 10 | 30 | 60 | 100 |
| AUC<sub>0-7hr</sub> | ng*Hours/mL     | 603 | 1990 | 6920 | 19200 | 29600 |
| AUC<sub>0-24hr</sub>  | ng*Hours/mL     | 1190 | 3550 | 10300 | 27400 | 46000 |
| AUC Extrap    | ng*Hours/mL     | NC | 3570 | 10300 | 27400 | 46000 |
| Cmax          | ng/mL           | 463 | 920 | 4020 | 10400 | 15600 |
| Tmax          | Hours           | 0.250 | 0.500 | 0.250 | 0.250 | 0.500 |
| T1/2          | Hours           | NC | 3.27 | 1.71 | 1.88 | 2.78 |
| AUC/Dose      | normalized      | 397 | 355 | 343 | 457 | 460 |

Data expressed as geometric mean

Abbreviations: AUC<sub>0-7hr</sub> = area under the curve from time 0 to 7 hours, AUC<sub>0-24hr</sub> = area under the curve from time 0 to 24 hours, AUC Extrap = area under the curve from time 0 to infinity, Cmax = maximum plasma concentration, NC = not calculated, Tmax = time of Cmax, T1/2 = half-life

Note: AUC is from plasma composite curve
**Supplementary Table 2**: Mevidalen Pharmacokinetic Parameters in Humans

|                | 15 mg     | 30 mg     | 75 mg     |
|----------------|-----------|-----------|-----------|
| N              | 12        | 13        | 12        |
| \(C_{\text{max}} \) (ng/mL) | 59.7 (30) | 113 (34)  | 293 (36)  |
| \(t_{\text{max}}^a\) (h)     | 3.00 (0.97 – 7.48) | 2.97 (1.03 – 8.90) | 3.07 (0.87 – 9.03) |
| AUC\(_{0-\infty}\) (ng×hr/mL) | 636 (49)\(^b\) | 1200 (46)\(^c\) | 3100 (42)\(^d\) |
| AUC\(_{0-24}\) (ng×hr/mL) | 521 (43)\(^b\) | 987 (43)\(^c\) | 2560 (39)\(^d\) |

Data expressed as geometric mean

Abbreviations: AUC\(_{0-\infty}\) = area under the concentration versus time curve from time 0 to infinite time; AUC\(_{0-24}\) = area under the concentration versus time curve from time 0 to 24 hours; \(C_{\text{max}}\) = maximum plasma concentration; N = number of subjects; \(t_{\text{max}}\) = time to \(C_{\text{max}}\).

\(^a\): Median (range)

\(^b\): N=11

\(^c\): N=12

\(^d\): N=9
Supplementary Table 3: Effects of mevidalen on NREM sleep in the hD1 mouse

Abbreviations: LS = least squares; NREM = non-rapid eye movement; SE = standard error. Est. = Estimate

| Outcome | Dose | N | LSMean | SE  | Est. | SE  | P     |
|---------|------|---|--------|-----|------|-----|-------|
|         | mg/kg|   |        |     |      |     |       |
| REM sleep latency (Latency between first NREM sleep epoch and 20s continuous REM sleep) | 0 | 21 | 35.47 | 6.13 |      |     |       |
|         | 3    | 17 | 32.47 | 6.24 | 0.92 | 0.24 | 0.7335 |
|         | 10   | 10 | 47.43 | 11.88| 1.34 | 0.41 | 0.3417 |
|         | 20   | 13 | 41.52 | 9.12 | 1.17 | 0.33 | 0.5744 |
|         | 30   | 11 | 45.14 | 10.78| 1.27 | 0.38 | 0.4151 |
|         | 60   | 12 | 33.30 | 7.61 | 0.94 | 0.27 | 0.8266 |
|         | 100  | 18 | 67.39 | 12.58| 1.90 | 0.48 | 0.0133 |
| REM Duration | 0 | 21 | 26.31 | 1.17 |      |     |       |
|         | 3    | 17 | 24.51 | 1.3  | -1.8 | 1.74 | 0.3054 |
|         | 10   | 10 | 22.66 | 1.69 | -3.65| 2.05 | 0.0788 |
|         | 20   | 13 | 14.64 | 1.48 | -11.67| 1.89 | <.0001 |
|         | 30   | 11 | 9.99  | 1.61 | -16.32| 1.99 | <.0001 |
|         | 60   | 12 | 5.55  | 1.55 | -20.76| 1.93 | <.0001 |
|         | 100  | 18 | 0.6   | 1.27 | -25.71| 1.73 | <.0001 |
| NREM Duration | 0 | 21 | 33.31 | 2.15 |      |     |       |
|         | 3    | 17 | 34.15 | 2.39 | 0.84 | 3.22 | 0.7943 |
|         | 10   | 10 | 34.23 | 3.12 | 0.92 | 3.79 | 0.8087 |
|         | 20   | 13 | 42.68 | 2.74 | 9.38 | 3.48 | 0.0083 |
|         | 30   | 11 | 48.31 | 2.98 | 15.01| 3.69 | <.0001 |
|         | 60   | 12 | 55.08 | 2.92 | 21.77| 3.65 | <.0001 |
|         | 100  | 18 | 41.56 | 2.34 | 8.25 | 3.17 | 0.0107 |
| REM Duration | 0 | 21 | 224.1 | 5.8  |      |     |       |
|         | 3    | 17 | 217.1 | 6.6  | -7.0 | 8.0  | 0.386  |
|                | 0      | 21   | 3    | 17   | 10   | 10   | 20   | 13   | 11   | 30   | 60   | 12   | 100  | 18   |
|----------------|--------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| **First 7-hrs post treatment (light)** |        |      |      |      |      |      |      |      |      |      |      |      |      |      |
| NREM Duration  |        |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 0              | 21     | 333.0| 8.2  |      |      |      |      |      |      |      |      |      |      |      |
| 3              | 17     | 323.5| 9.0  | -6.5 | 9.2  | 0.485|      |      |      |      |      |      |      |      |
| 10             | 10     | 338.3| 11.0 | 8.3  | 11.4 | 0.473|      |      |      |      |      |      |      |      |
| 20             | 13     | 351.6| 10.6 | 21.5 | 10.0 | 0.035|      |      |      |      |      |      |      |      |
| 30             | 11     | 355.1| 11.2 | 25.1 | 11.7 | 0.036|      |      |      |      |      |      |      |      |
| 60             | 12     | 344.2| 12.0 | 4.1  | 12.1 | 0.734|      |      |      |      |      |      |      |      |
| 100            | 18     | 319.9| 8.6  | -10.1| 8.7  | 0.252|      |      |      |      |      |      |      |      |
| **Average wake bout length** |        |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 0              | 21     | 30.08| 2.06 |      |      |      |      |      |      |      |      |      |      |      |
| 3              | 17     | 44.24| 3.37 | 1.47 | 0.15 | 0.0003|      |      |      |      |      |      |      |      |
| 10             | 10     | 57.51| 5.72 | 1.91 | 0.23 | <.0001|      |      |      |      |      |      |      |      |
| 20             | 13     | 135.4| 11.81| 4.5  | 0.5  | <.0001|      |      |      |      |      |      |      |      |
| 30             | 11     | 147.47| 13.99| 4.9  | 0.57 | <.0001|      |      |      |      |      |      |      |      |
| 60             | 12     | 179.12| 16.26| 5.96 | 0.68 | <.0001|      |      |      |      |      |      |      |      |
| 100            | 18     | 174.59| 12.94| 5.81 | 0.59 | <.0001|      |      |      |      |      |      |      |      |
| **Body Temperature change vs baseline (°C)** |        |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 0              | 21     | -0.31| 0.06 |      |      |      |      |      |      |      |      |      |      |      |
| 3              | 17     | -0.19| 0.07 | 0.12 | 0.09 | 0.2077|      |      |      |      |      |      |      |      |
| 10             | 10     | -0.15| 0.08 | 0.16 | 0.1  | 0.106|      |      |      |      |      |      |      |      |
| 20             | 13     | 0.17 | 0.07 | 0.48 | 0.09 | <.0001|      |      |      |      |      |      |      |      |
| 30             | 11     | 0.14 | 0.09 | 0.45 | 0.11 | <.0001|      |      |      |      |      |      |      |      |
| 60             | 12     | 0.67 | 0.09 | 0.99 | 0.11 | <.0001|      |      |      |      |      |      |      |      |
| 100            | 18     | 0.7  | 0.07 | 1.01 | 0.09 | <.0001|      |      |      |      |      |      |      |      |
| **Locomotor Activity Counts** |        |      |      |      |      |      |      |      |      |      |      |      |      |      |
| 0              | 21     | 3444.5| 471.2|      |      |      |      |      |      |      |      |      |      |      |
| 3              | 17     | 4283.8| 552.51| 12564| 701.64| <.0001|      |      |      |      |      |      |      |     
### Supplementary Table 4: Effects of mevidalen on sleep during the recovery night in humans

| Measure                      | Parameter | Placebo (n=16) | 15 mg mevidalen (n=12) | 30 mg mevidalen (n=13) | 75 mg mevidalen (n=12) | 200 mg (n=12) modafinil |
|------------------------------|-----------|----------------|------------------------|------------------------|------------------------|-------------------------|
|                              |           | Lps Mean       | 7.03                   | 3.46                   | 7.31                   | 15.25                   | 5.88                    |
|                              |           | Lps Sd         | 8.82                   | 3.90                   | 8.55                   | 17.27                   | 3.64                    |
|                              |           | Lrems Mean     | 61.59                  | 50.21                  | 53.65                  | 70.92                   | 62.33                   |
|                              |           | Lrems Sd       | 40.46                  | 22.63                  | 25.45                  | 19.26                   | 45.00                   |
|                              |           | N1 % Mean      | 4.98                   | 5.55                   | 5.03                   | 7.68                    | 7.17                    |
|                              |           | N1 % Sd        | 2.83                   | 3.59                   | 2.77                   | 3.63                    | 3.42                    |
|                              |           | N1 duration Mean | 25.00              | 26.42                  | 23.46                  | 35.88                   | 32.75                   |
|                              |           | N1 duration Sd | 13.01                  | 15.70                  | 10.88                  | 16.06                   | 13.33                   |
|                              |           | N1 latency Mean | 21.59                 | 19.63                  | 0                      | 0                       | 0.13                    |
|                              |           | N1 latency Sd  | 62.73                  | 30.94                  | 0                      | 0                       | 0.43                    |
|                              |           | N2 % Mean      | 46.20                  | 43.13                  | 48.11                  | 47.60                   | 45.36                   |
|                              |           | N2 % Sd        | 11.15                  | 8.26                   | 11.95                  | 8.28                    | 11.11                   |
|                              |           | N2 duration Mean | 237.41             | 215.21                 | 235.81                 | 225.96                  | 214.75                  |
|                              |           | N2 duration Sd | 54.70                  | 51.38                  | 69.57                  | 50.09                   | 55.29                   |
|                | Mean   | 2.25  | 2.00  | 3.00  | 4.42  | 4.83  |
|----------------|--------|-------|-------|-------|-------|-------|
|                | Sd     | 2.32  | 3.07  | 3.83  | 4.68  | 7.95  |
| N2 latency     |        |       |       |       |       |       |
| N3 %           | Mean   | 22.51 | 25.54 | 23.48 | 23.88 | 24.98 |
|                | Sd     | 7.97  | 8.25  | 7.73  | 6.84  | 7.91  |
| N3 %           |        |       |       |       |       |       |
| N3 duration    | Mean   | 116.47| 125.50| 114.27| 112.04| 118.46|
|                | Sd     | 43.68 | 39.92 | 38.99 | 30.21 | 38.60 |
| N3 latency     |        |       |       |       |       |       |
|                | Mean   | 8.88  | 6.29  | 4.93  | 11.44 | 15.00 |
|                | Sd     | 7.30  | 5.71  | 4.32  | 11.44 | 15.00 |
|                |        |       |       |       |       |       |
| N3 latency     |        |       |       |       |       |       |
|                | Mean   | 22.44 | 21.58 | 23.15 | 28.17 | 27.17 |
|                | Sd     | 7.79  | 7.25  | 5.81  | 8.30  | 5.65  |
| Naw            |        |       |       |       |       |       |
| Naw            | Mean   | 378.88| 367.13| 373.54| 373.88| 365.96|
|                | Sd     | 39.68 | 41.80 | 53.76 | 36.72 | 43.33 |
| N3 duration    |        |       |       |       |       |       |
|                | Mean   | 26.32 | 25.77 | 23.37 | 20.83 | 22.49 |
|                | Sd     | 7.33  | 6.32  | 5.31  | 6.20  | 8.18  |
| Naw            |        |       |       |       |       |       |
| Naw            | Mean   | 136.56| 128.42| 113.73| 101.29| 109.29|
|                | Sd     | 40.54 | 38.05 | 28.30 | 37.98 | 46.20 |
| N3 duration    |        |       |       |       |       |       |
|                | Mean   | 93.99 | 92.33 | 90.52 | 87.60 | 89.03 |
|                | Sd     | 3.38  | 6.00  | 7.00  | 7.10  | 7.00  |
| Naw            |        |       |       |       |       |       |
| Naw            | Mean   | 2.97  | 2.21  | 5.73  | 9.29  | 3.67  |
|                | Sd     | 5.58  | 2.39  | 7.32  | 11.66 | 3.33  |
| N3 duration    |        |       |       |       |       |       |
|                | Mean   | 547.41| 535.29| 537.15| 540.92| 531.83|
|                | Sd     | 37.02 | 41.66 | 43.35 | 39.81 | 40.13 |
| Naw            |        |       |       |       |       |       |
| Naw            | Mean   | 515.44| 495.54| 487.27| 475.17| 475.25|
|                | Sd     | 44.07 | 48.74 | 59.77 | 59.70 | 61.94 |
| N3 duration    |        |       |       |       |       |       |
|                | Mean   | 31.97 | 39.75 | 49.88 | 65.75 | 56.58 |
|                | Sd     | 17.78 | 33.40 | 36.61 | 34.21 | 35.23 |
| Naw            |        |       |       |       |       |       |
| Naw            | Mean   | 29.00 | 37.54 | 44.15 | 56.46 | 52.92 |
|                | Sd     | 15.88 | 32.16 | 34.38 | 28.65 | 33.40 |

Abbreviations: PSG = Polysomnography; N = number of subjects in the Full Analysis Set; n = number of subjects with observations; SD = standard deviation; Lps = Latency to persistant sleep; Lrems = Latency REM sleep; N1 DURATION = Time in Stage N1 Sleep; N2 DURATION = Time in Stage N2 Sleep; N3 DURATION = Time in Stage N3 Sleep; N3 LATENCY = Latency to Stage N3 Sleep; Sol = Sleep onset latency; Tib = Time in bed; Tst = Total sleep time; NAW = Number of Awakenings; Waso = Wake after sleep onset.
Supplementary Figure 1: Mevidalen Pharmacokinetic Profiles in satellite fed male CD-1 mice
(N=6 per dose group with 3/timepoint) as a single oral dose of 3, 10, 30, 60 and 100 mg/kg. Plots showing mean and standard error of observed data.
Supplementary Figure 2: Mevidalen Pharmacokinetic Profiles in Humans. 15 mg: n= 12, 30 mg: n= 12, 75 mg: n=12. Plots showing mean and standard error of observed data.